報價延遲最少15分鐘:2026/04/25 23:00 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.33 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-7.84/-24.00
|
|
企業價值
9.68M
|
| 資產負債 |
|
每股賬面淨值
5.84
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
0.49
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Tivic Health Systems Inc is a late-stage biopharmaceutical company focused on the development of biologics, with its lead product candidate, Entolimod, a TLR5 agonist, being developed for acute radiation syndrome and oncology-related indications. The company operates through two segments: a biopharma segment focused on product development and commercialization, and a contract development and manufacturing organization (CDMO) segment providing manufacturing and development services through its subsidiary. |
